Philips receives FDA De Novo Clearance for IVC filter removal laser sheath

CavaClear is a FDA-cleared solution for advanced IVC filter removal

Philips received FDA De Novo Clearance for CavaClear, an IVC filter removal laser sheath
Philips received FDA De Novo Clearance for CavaClear, an IVC filter removal laser sheath

Royal Philips, a global leader in health technology, announced the FDA has granted De Novo Clearance for Philips IVC filter removal laser sheath, CavaClear, to remove an IVC filter when previous removal methods have failed. CavaClear is the first and only FDA-cleared solution for advanced IVC filter removal. Earlier in 2021, the FDA granted the device breakthrough device designation. Laser has been clinically proven to provide a success rate of over 99%, with low complication rates.

IVC filters are used to treat patients with venous thromboembolism, in which blood clots form in the deep veins of the leg and groin and can travel through the circulatory system. They are placed in the inferior vena cava to capture blood clots from moving to the lungs. However, research has shown that IVC filters may have long-term complications. The filters can fracture and travel through the bloodstream to other body parts. Other identified long-term risks associated with IVC filters include lower limb deep vein thrombosis and IVC occlusion. The FDA recommends that implanting physicians consider removing retrievable IVC filters as soon as they are no longer indicated.

Philips’ CavaClear gives numerous options for IVC filter removal operations

Failure rates for IVC filter removal can be high, and before CavaClear, limited options for removal existed if the filter became challenging to remove. Advanced retrieval tools and techniques are required if the IVC filter becomes embedded in the vasculature. Physicians previously had very few tools to remove the filter when complications occurred, and until now, there were no FDA-approved devices for this type of advanced removal.

“Today is a historic day. With the approval of CavaClear, physicians now have a device specifically geared to remove chronically embedded IVC filters,” said Kush R. Desai, medical director, FSIR, associate professor of Radiology, Surgery, and Medicine, and director of Deep Venous Interventions at Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. “Backed by evidence, this technology can be applied to retrieve IVC filters that are no longer indicated, reducing potential clinical risk for patients and satisfying the FDA’s guidance to retrieve filters when they are no longer indicated.”

Clinical research supports laser-assisted removal

Two independent and prospective clinical studies demonstrated that laser-assisted retrieval was 96-99.4% effective with a major adverse event rate of 0.7-2%. Philips CavaClear uses circumferential tissue ablation that can aid in capturing the filter within seconds of laser activation, which can help increase physician efficiency during removal and may help lower costs by reducing the number of retrieval attempts needed to remove an embedded filter. In addition, the simple and safe design is easy for physicians to integrate into their workflow.  

“With the FDA’s clearance of our IVC filter removal laser sheath, CavaClear, more than one million patients and their physicians now have access to a safe, effective and efficient option for advanced IVC filter removal,” said Chris Landon, senior vice-president and general manager Image Guided Therapy Devices at Philips. “This clearance demonstrates the commitment of Philips to innovating procedures with physician collaboration to meet unmet needs that can have a critical impact on the lives of patients and their families.”


Please enter your comment!
Please enter your name here